Masimo在周三向美国哥伦比亚特区联邦地区法院提交的起诉书中称，CBP在8月1日的一份内部咨询裁 定中越权行事，该裁定在没有通知或征求Masimo意见的情况下，推翻了其1月份的决定。Masimo依据 《行政程序法》以及《第五修正案》中的正当程序条款提出了诉讼请求。 Masimo周三还请求法院发布临时限制令和初步禁令，以阻止CBP 8月1日裁定的执行。该公司希望恢复1 月份的决定，该决定是在苹果和Masimo 双方均参与的程序中作出的，规定只有在血氧监测功能被禁用 的情况下，相关产品才可进口。(作者/箫雨) 然而，苹果在今年8月14日宣布，将通过软件更新为美国Apple Watch用户恢复血氧监测功能，方式是把 计算过程转移到与其配对的iPhone上，而不是在手表本身完成。 Masimo表示，这是他们首次得知CBP已在两周前通过一项单方面裁定悄然推翻了原先决定，而该机构 的政策通常要求此类裁定必须听取双方意见。 凤凰网科技讯 北京时间8月21日，据彭博社法律网站报道，健康科技公司Masimo起诉了美国海关与边 境保护局(CBP)，指控CBP非法允许苹果在Apple Watch上重新启用一项侵犯其专利的血氧监测 ...

Group 1 - The core issue involves China’s Datang Mobile filing three patent lawsuits against Xiaomi in a German court, focusing on LTE/4G technology patents that are crucial for both 4G and 5G technologies [2] - The patents in question include EP2237607 (method and device for handover), EP3713313 (uplink power control method and mobile communication terminal), and EP2315369 (adaptive modulation and coding method and device) [2] - Datang Mobile, a wholly-owned subsidiary of China’s Zhongxing Telecommunication Equipment Corporation, previously won a similar lawsuit against Samsung in Germany regarding the same patent [2] Group 2 - Datang Mobile has opted for litigation in foreign jurisdictions to resolve standard essential patent licensing disputes, following a trend seen with other Chinese companies like Lenovo and ZTE [3] - The choice of Germany for such lawsuits is strategic, as German courts are known for their leniency in granting injunctions for patent infringements, which could lead to product bans [3] - The timing of the lawsuit coincides with Xiaomi's recent release of its self-developed 4G watch chip, although the lawsuit is not directly related to this chip as the products based on it have not yet been sold in Germany [3]

Core Viewpoint - China’s Datang Mobile has initiated three lawsuits against Xiaomi in Germany regarding 4G-related patents, which are crucial for both 4G and 5G technologies [1][2]. Group 1: Patent Lawsuits - The lawsuits involve three LTE/4G patents: EP2237607 (method and device for handover), EP3713313 (uplink power control method and mobile communication terminal), and EP2315369 (adaptive modulation and coding method and device) [1]. - Datang Mobile previously won a lawsuit against Samsung in Germany concerning the EP2237607 patent, which is essential for seamless connectivity in 4G technology [2]. Group 2: Context and Implications - The timing of the lawsuit coincides with Xiaomi's release of its self-developed 4G watch chip, but the lawsuit is likely related to Xiaomi's smartphone and communication products rather than the new chip [2]. - Datang Mobile has successfully negotiated patent licenses with several global smartphone manufacturers, including Apple and Lenovo, without resorting to litigation [3]. - The legal landscape in Germany is noted for its leniency in granting injunctions for patent infringement, which could lead to significant consequences for Xiaomi if the court rules against them [3].

Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].